



# PROGRAMME

Version 5 (SUBJECT TO ALTERATION)

**Tuesday 18th October**

**FLEMING ROOM**

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 **Welcome / Housekeeping**

## SOFT TISSUE SARCOMA

08.35	216	Elbow synovial sarcoma - biopsy and imaging challenges in recurrent disease - case presentation. <i>Dr Mihai Nica, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</i>
08.40	19	Synovial sarcoma: A clinicopathological study. <i>Dr Mustafa Karaca, Ankara University Medical Faculty, Ankara, Turkey</i>
08.45	302	Mixoinflammatory fibroblastic sarcoma: a case series from two sarcoma centre. <i>Dr Marco Focaccia, Orthopedic Oncology Division, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy</i>
08.50	77	What treatment modality is associated with a better prognosis in patients with localized/metastatic clear cell sarcoma? A population-based study. <i>Dr Tomohiro Fujiwara, Okayama University Hospital, Okayama, Japan</i>
08.55	114	Intermuscular extremity myxoid liposarcoma can be managed by marginal resection following neoadjuvant radiotherapy. <i>Mr Jonathan Perera, RNOH, UK</i>
09.00		Questions

- 09.10 148 Evaluation of the effect of neoadjuvant chemotherapy on the resectability of extremity soft-tissue sarcoma. *Prof David Biau, Hôpital Cochin, Paris, France*
- 09.15 268 Soft tissue sarcomas in elderly patients: do we have to operate always? *Dr Michele Boffano, Orthopaedic Oncology AOU Citta' della Salute e della Scienza, Torino, Italy*
- 09.20 28 Vascular Proximity increase the risk of local recurrence in Soft-Tissue Sarcomas of the thigh - A retrospective MRI study. *Dr Andrea Sambri, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy*
- 09.25 Questions
- 09.40 253 Free fillet flaps for reconstruction of massive oncologic resections. *Dr Lucas Kreutz Rodrigues, Mayo Clinic, Rochester, USA*
- 09.45 336 The orthoplastic approach in soft tissue tumors of the foot. *Prof Pietro Ruggieri, Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy, Padova, Italy*
- 09.50 267 Wound healing complication after excision of soft tissue sarcomas: does it delay radiologic follow up and increase local recurrence rate? *Dr Michele Boffano, Orthopaedic Oncology AOU Citta' della Salute e della Scienza, Torino, Italy*
- 09.55 296 Unplanned excision of soft tissue sarcomas of the hand and the wrist. *Prof Vasileios Kontogeorgakos, First Department of Orthopedic Surgery, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece*
- 10.00 43 Unplanned resections of soft tissue sarcomas – is further surgery necessary in every case? *Prof Hans Roland Dürr, Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 10.05 Questions
- 10.15 **REFRESHMENTS**
- KEYNOTE LECTURE**
- 10.45 Research in Rare Tumours - How to Collaborate  
*Prof Michiel Van de Sande, Professor of Orthopaedic Oncology, Leiden University Medical Centre, Leiden, Netherlands*
- 11.20 **CASE DISCUSSIONS / DEBATE**
- PRESIDENTIAL LECTURE**
- 11.50 Progresses and future directions in musculoskeletal oncology and the role of International Societies  
*Prof Pietro Ruggieri, Padua, Italy*

12.30 **LUNCH**

**IMPLANTCAST SYMPOSIUM**

**Chairs / Moderators:** *Mr. Rob Pollock, Royal National Orthopaedic Hospital, Stanmore, United Kingdom*

*Prof. Pietro Ruggieri, University of Padova, Italy*

- 12.30 LUMiC® or 3D printed pelvic implants for sarcoma? *Prof Lee Jeys, Royal Orthopaedic Hospital, Birmingham, UK*
- 12.40 How the choice of surgical technique can influence clinical outcome in patients with 3D printed implants? *Prof. Daniel Kotrych, Szczecin, Poland*
- 12.50 Osteointegration of custom made implants, *Prof. Thomas Schubert, Brussels, Belgium*
- 13.00 Case reports: 1. Telangiectatic osteosarcoma of the pelvis 2. Secondary Chondrosarcoma in a Patient with Maffucci Syndrome. *Dr. Hazem Wafa, Head of Clinic, Orthopaedic Oncology and Knee Surgery, UZ, Leuven, Belgium*
- 13.10 Novel joint sparing implants, the London experience. *Mr Rob Pollock, Royal National Orthopaedic Hospital, Stanmore, UK*
- 13.20 Long term results of MUTARS® implants – analysis of 187 cases. *Dr. Elisa Pala, University of Padova, Italy*

**CHONDRAL TUMOURS**

**KEYNOTE LECTURE**

- 13.30 Controversies in Chondrosarcoma  
*Prof Lee Jeys. Professor of Orthopaedic Oncology, Royal Orthopaedic Hospital, Birmingham, UK*

**ENCHONDROMAS + ACT**

- 13.45 242 The past, present and future in treatment of Atypical Cartilaginous Tumours. *Ms Claudia Deckers, Department of Orthopedics, Radboudumc, Nijmegen, Netherlands*
- 13.50 236 Outcome after intralesional curettage of highly-differentiated chondrosarcomas/atypical cartilaginous tumors (ACTs) of the extremities. *Prof Georg Omlor, University of Heidelberg, Department of Orthopaedic Surgery, Heidelberg, Germany*
- 13.55 Circulating tumour cells during surgery for chondral tumours. *Dr Mike Cooper, Royal National Orthopaedic Hospital, Stanmore, UK*
- 14.00 316 Enchondroma and atypical cartilaginous tumor: To operate or not to operate. *Dr Berkay Doğan, Baltalimani Bone Diseases Training and Research Hospital, Istanbul, Turkey*
- 14.05 130 Review of 23 patients with low-grade chondrosarcoma who underwent surgical treatment, is intra-lesional curettage enough? *Dr Filipe Castelo, Centro Hospitalar Universitário do Porto, Porto, Portugal*
- 14.10 338 Limb lengthening for deformities in Ollier's disease: a systematic review in 121 patients (272 bone segments). *Prof Pietro Ruggieri, Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy, Padova, Italy*
- 14.15 Questions

## CHONDROSARCOMA

- 14.30 150 Chondrosarcomas of the pelvis: about 106 operated cases. *Prof David Biau, Hôpital Cochin, Paris, France*
- 14.37 151 Excision of 87 primary malignant bone tumors of the pelvis. *Prof David Biau, Hôpital Cochin, Paris, France*
- 14.44 212 Outcome of surgical treatment of chondrosarcoma of the extremities and impact of surgical revision. *Prof Philipp Funovics, Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Vienna, Austria*
- 14.51 46 Chondrosarcoma of the chest wall: A single-institution review of 50 cases. *Mrs Mina Laitinen, Helsinki University Hospital, Helsinki, Finland*
- 14.58 97 Extraosseous tumour component predicts disease specific survival better than the grade in conventional central chondrosarcoma of the proximal femur. *Prof Lee Jeys, Royal Orthopaedic Hospital, Birmingham, United Kingdom*
- 15.05 96 Dedifferentiated central chondrosarcoma. *Prof Lee Jeys, Royal Orthopaedic Hospital, Birmingham, United Kingdom*
- 15.12 64 Impact of insurance status on chondrosarcoma diagnostic stage: implications for detection and outcomes. *Dr Ana Cecilia Belzarena, Miami Cancer Institute, Miami, USA*
- 15.19 Questions

## 15.30 REFRESHMENTS

## 16.00 EEC EWINGS SYMPOSIUM

### **Ewing Sarcoma – current challenges in local treatment and future perspectives.**

*CHAIRS: Dr Dimosthenis Andreou - Division Chair Orthopedic Oncology at the Department of Orthopedics and Trauma, Medical University Graz, Austria. Prof. Dr. med. Beate Timmermann, Director of the Particle Therapy Clinic and Head of Medicine at the West German Proton Therapy Centre in Essen, Essen University Hospital, Germany*

### **Upcoming international Ewing sarcoma trials - an update**

Inter-Ewing-1. *Dr JHM Merks, Princess Máxima Center for Pediatric Oncology, Netherlands*

iEuroEwing. *Professor Uta Dirksen, University Hospital Essen, Germany*

Discussion

### **Interactive MDT – how would you locally treat these challenging cases?**

Discussion of 3-4 cases in an MDT format, short presentation of available evidence, followed by public voting

## CAMPANACCI LECTURE

- 17.30 A journey in orthopaedic oncology from London to Sydney and back again - staring with the "Dirty Dozen"  
*Prof Paul Stalley, OA, Sydney*

- 19.30 Gala Dinner

## Tuesday 18th October

### WHITTLE ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 **Welcome / Housekeeping**

#### SPINE & SACRAL TUMOURS

08.35 75 Epidemiology of surgically treated spinal tumors according to the German Society for Spine Surgery (DWG) registry. Dr Peter Knoell, *University Hospital Cologne, Cologne, Germany*

08.40 177 Surgical outcomes in patients operated for symptomatic metastatic spinal cord compression: A single institutional analysis to determine the change in quality of life and prognostic indicators for surgery. Dr Amrithlal Mascarenhas, *HCG Hospital, Bangalore, India*

08.45

08.55 Questions

09.05 219 A preliminary Comparison of CT-guided Navigation-assisted Surgery versus conventional surgical Treatment of Osteoid Osteoma in the Spine. Dr Gerhard Hobusch, *Department of Orthopedic and Trauma Surgery, Medical University of Vienna, Vienna, Austria*

09.10 339 Decompressive surgery for spine metastases: analysis of 49 patients from a single Institute. Prof Pietro Ruggieri, *Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy, Padova, Italy*

09.15 297 Surgical Treatment of Sacral Chordomas. A Retrospective Study of 26 cases. Dr Ioannis Trikoupis, *First Department of Orthopaedic Surgery, National and Kapodistrian University of Athens, Medical School, Attikon University General Hospital, Athens, Greece*

09.20 334 Modified surgical technique of sacrectomy in treatment of bone sarcoma and its impact on function and overall survival. Prof Daniel Kotrych, *SPomeranian Medical University, Szczecin, Poland*

09.25 142 Cryoablation of sacral Giant Cell Tumor using 3D printing: a case report. Mr Eran Golden, *Levin Center of Surgical Innovation & 3D Printing, Tel Aviv, Israel*

09.30 Questions

09.40 **INTERACTIVE SPINE AND SACRAL TUMOUR SESSION WITH CASE DISCUSSIONS**

10.15 **REFRESHMENTS**

**TENO-SYNOVIAL GIANT CELL TUMOURS**

- 10.45 162 Phototherapy in the Treatment of tenosynovial giant cell tumor. *Prof Frank Traub, Department of Orthopaedics and Traumatology, University Medical Center of the Johannes Gutenberg University,, Mainz, Germany*
- 10.50 238 Tenosynovial Giant Cell Tumour of the hip: Therapy, Results. *Dr Alexander Klein, Orthopaedic Oncology; Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 10.55 258 One versus two-stage synovectomy of diffuse-type tenosynovial giant cell tumor (D-TGCT) of the knee: an international, retrospective, cohort study. *Mr Geert Spierenburg. Leiden University Medical Center, Leiden, Netherlands*
- 11.00 260 Active surveillance of diffuse-type tenosynovial giant cell tumors: a retrospective, multicenter cohort study. *Mr Geert Spierenburg. Leiden University Medical Center, Leiden, Netherlands*
- 11.05 283 Outcomes of tenosynovial giant cell tumour of the foot and ankle. *Mr James Barnett, Royal National Orthopaedic Hospital, Stanmore, United Kingdom*
- 11.10 Questions

**GCT OF BONE**

- 11.15 76 Intralesional curettage and bone graft for the treatment of bone GCT. Experience in a single institution since 1982. *Dr Ididre Gracia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*
- 11.20 106 Reduced dose intensity protocol of denosumab in treating advanced/unresectable giant cell tumour of the bone. *Dr Suraj Hindiskere, HCG Hospital, Bangalore, India*
- 11.25 168 Neoadjuvant denosumab in GCT: long term injection can decrease the risk of local recurrence. *Anastasia Tararykova, (N.N. Blokhin NMRCO), Moscow, Russian Federation*
- 11.30 181 Treatment of Giant Cell Tumor of Bone in the Distal Radius and Ulna. *Dr Michal Mahdal, First Department of Orthopedic Surgery, St. Anne's University Hospital, Brno, Czech Republic*
- 11.35 208 Secondary malignancy in giant cell tumor in the extremity: a single-center experience. *Dr Taemin Hong, Department of Orthopaedic Surgery, Incheon St. Mary's Hospital, Colloge of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of*
- 11.40 Questions

12.30 **LUNCH**

## LONG TERM FUNCTIONAL OUTCOMES FOLLOWING DIAGNOSIS. JOINT SESSION WITH AHP

- 13.30 123 Providing insight in a patients' physical functioning in musculoskeletal oncology. *Ms Jorinde Denissen, Nijmegen, Netherlands*
- 13.38 140 Functional outcomes in patients undergoing resection and reconstruction surgery of proximal femur or pelvis bones after malignant bone tumor. A case series. *Dr Matilde Meneghini, Istituto Ortopedico Rizzoli, Bologna, Italy*
- 13.46 141 Patient experience connected to mobility, physical function and rehabilitation following lower limb salvage surgery for sarcoma. *Shea Byrne, RNOH, UK*
- 13.54 47 Long-term gait analysis after a rotationplasty, a cross-sectional follow-up study. *Ms Gitte Krebbekx, Amsterdam UMC (AMC), Amsterdam, Netherlands*
- 14.02 325 Stanmore Tumour Outcomes Project (STOMP): What is the patients' survivorship experience after extremity sarcomas? – A presentation of preliminary findings. *Ms Teja Joshi, Royal National Orthopaedic Hospital, London, United Kingdom*
- 14.10 Questions
- 14.20 272 Balance and Gait Outcomes after 1-year post-operative Hemipelvectomy Surgery? *Dr Sherron Furtado, Royal National Orthopaedic Hospital NHS Trust (RNOH), London, United Kingdom*
- 14.28 264 Life quality and functionality after internal hemipelvectomy. *Prof Burkhard Lehner, Orthopedic university clinic, Heidelberg, Germany*
- 14.36 9 Predictors of functional recovery among musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction. *Dr Aaron Gazendam, McMaster Hospital, Hamilton, Canada*
- 14.44 221 What are the survivorship issues that occur following proximal femoral replacement surgery for musculoskeletal cancer? A Systematic Review. *Dr Sherron Furtado, JRU, Royal National Orthopaedic Hospital NHS Trust (RNOH), London, United Kingdom*
- 15.52 Questions

## INVITED LECTURE

- 15.02 Mental and Physical Wellbeing in Sarcoma - not just for patients  
*Speaker TBC*

## 15.30 REFRESHMENTS

## OUTCOMES AND SCORING SYSTEMS

- 16.00 8 Defining minimally important differences in functional outcomes for musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction. *Dr Aaron Gazendam, McMaster Hospital, Hamilton, Canada*

16.08	95	Patient engagement in sarcoma research: benefits, challenges, importance, and implications. <i>Ms Caitlyn Ivany, McMaster University, Hamilton, Canada</i>
16.16	329	The Sarcoma-Specific Quality of Life Study (SARC-QoL): identifying key domains of health-related quality of life in adult patients with extremity soft tissue sarcoma. <i>Dr Krista Goulding, Mayo Clinic Arizona, Phoenix, USA</i>
16.24	330	Patient-reported outcome measures to measure health-related quality of life in people with soft-tissue sarcoma: a systematic review of measurement properties of patient-reported outcomes. <i>Dr Krista Goulding, Mayo Clinic Arizona, Phoenix, USA</i>
16.32		Questions
16.42	331	A systematic review of patient-reported outcomes used to measure health-related quality of life in soft-tissue sarcoma. <i>Dr Krista Goulding, Mayo Clinic Arizona, Phoenix, USA</i>
16.50	152	Establishing a sarcoma reference score for EQ-5D. <i>Mr Cédric Niggli, University Hospital Zurich, Zurich, Switzerland</i>
16.58	305	Meaningful interpretation of Toronto Extremity Salvage Score in people with soft-tissue sarcoma using Rasch analysis. <i>Dr Krista Goulding, McGill University Health Centre, Montreal, Canada</i>
17.06	256	Outcomes of Bone Sarcoma in the Over 90's. <i>Dr Laura Hartley, The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, United Kingdom</i>
17.14	166	Comparative Survival Times for Patients Following Endoprosthetic Reconstruction After Primary and Metastatic Bone Tumour Resection Based on Disease Spread: A Retrospective Tertiary Centre Study. <i>Ms Jessica Harewood, Newcastle University, Faculty of Medical Sciences, Newcastle, United Kingdom</i>
17.20		Questions
17.30		<b>Close of Session</b>

## Tuesday 18th October

### GIELGUD ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30		<b>Welcome / Housekeeping</b>
-------	--	-------------------------------

### RADIOLOGY



- 08.35 31 Prevalence and characteristics of benign cartilaginous tumours of the knee joint as identified on MRI scans. *Mr Johannes Nikolaus Woltsche, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria*
- 08.40 87 How accurate is measurement on radiological images for resection and reconstruction in Orthopedic Oncology? *Dr Anto Gopurathingal, HCG Hospital, Bangalore, India*
- 08.45 225 A Deep Learning Model for Classification of Chondroid Tumors on CT-Images. *Dr Alexander Klein, Orthopaedic Oncology; Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 08.50 197 Dual time point [18F]FDG PET/CT can differentiate benign from malignant musculoskeletal tumors. *Prof Thomas Schubert, Cliniques universitaires Saint-Luc, Department of Orthopaedic Surgery, Brussels, Belgium*
- 08.55 34 Artificial Intelligence Algorithm can predict the clinical course of Desmoid Tumors using Baseline MRI - A Feasibility study. *Dr Amir Sternheim, National Unit of Orthopaedic Oncology Tel-Aviv Medical Center, Tel-Aviv, Israel*
- 09.00 206 Is it safe to send patients with tumor endoprosthesis to MRI? Heating and displacement force testing of tumor endoprosthesis within the MR field. *Dr Marko Bergovec, Medical University Graz, Graz, Austria*
- 09.05 Questions
- 09.15 60 Diagnostic accuracy of the biopsy of soft tissue component of bone tumour with soft tissue extension. *Dr Idowu O.K, Oncology Unit, National Orthopedic Hospital Igbobi, Lagos, Nigeria.*
- 09.20 105 Preoperative imaging determines necessity of tissue biopsy in extraperitoneal lipomatous tumor. *Dr Chindanai Hongsaprabhas, Department of Orthopaedics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand*
- 09.25 99 Clinical and imaging features affecting the necessity of tissue biopsy in pathological long bone fractures. Department of Orthopaedics. *Dr Chindanai Hongsaprabhas, Department of Orthopaedics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand*
- 09.30 192 Does the histological presence of a nidus correlate with improved outcomes in osteoid osteoma treated with percutaneous radiofrequency ablation (RFA)? *Mr Amirul Adllan, Royal Orthopaedic Hospital, Birmingham, United Kingdom*
- 09.35 82 An Update Of Technical Tips Of Microwave Ablation and Ct-Guided Radiofrequency Ablation As A Part Of Minimally Invasive Techniques In Orthopedic Oncology - A Review Of 70 Cases From A Tertiary Care Center In India. *Dr Amar Kamat, HCG Hospital, Bangalore, India*
- 09.40 41 Incidental benign bone tumors on knee radiographs. *Dr Kamil Balaban, Ankara University Faculty of Medicine, Department of Orthopedics and Traumatology, Ankara, Turkey*
- 09.45 Questions

09.55 **DEBATE**

10.15 **REFRESHMENTS**

## MANAGING BLOOD LOSS IN ORTHOPAEDIC ONCOLOGY

- 10.45 48 Use of tranexamic acid to reduce post-operative bleeding in orthopaedic oncology. Dr Lorenzo Andreani, Universty of Pisa, Pisa, Italy
- 10.50 81 Prospective Evaluation of Tranexamic Acid in Metastatic Cancer Patients with Pathologic Fractures Treated with Total Hip Arthroplasty or Hemiarthroplasty. *Dr Caleb Yeung, Memorial Sloan Kettering Cancer Center, New York, USA*
- 10.55 298 The Safety and Efficacy of Tranexamic Acid in Oncology Patients Undergoing Endoprosthetic Reconstruction and a ROTEM-Based Evaluation of Their Hemostatic Profile: A Pilot Study. *Dr Ioannis Trikoupis, National and Kapodistrian University of Athens, Athens, Greece*
- 11.00 146 Reduction of blood loss by tranexamic acid in cases of lower extremity tumor resection and modular tomor endoprosthesis. *Prof Burkhard Lehner, Orthopedic university clinic, Heidelberg, Germany*
- 11.05 Questions
- 11.15 10 Tourniquet use in patients undergoing oncologic resection and endoprosthetic reconstruction of the knee. *Ms Patricia Schneider, McMaster University, Hamilton, Canada*
- 11.20 120 Use of regional anesthesia to reduce blood loss in isolated limb perfusion (ILP) - a pilot study. *Dr Maya Niethard, Department of Orthopedic Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany*
- 11.25 Intra-operative TEG data to cutomise VTE risk and individualise care for sarcoma patients. *Dr Mike Cooper, RNOH, UK*
- 11.30 Questions
- 11.40 **Close**

## 12.30 LUNCH

## BASIC SCIENCE

- 13.30 33 5-ALA-dependent fluorescence of musculoskeletal tumors in a chick chorio-allantoic membrane model. *Dr Wiebke Katharina Guder, Department of Orthopedic Oncology, University Hospital Essen, Essen, Germany*
- 13.36 39 In vivo massive bone allografts decellularized by a new perfusion process: preliminary results. *Dr Robin Evrard, Université Catholique de Louvain, Institut de recherche expérimentale et clinique, Chirurgie expérimentale et transplantation (CHEX), Brussels, Belgium*
- 13.42 254 Evaluation of candidate biomarkers for fluorescence-guided surgery in myxofibrosarcoma: An immunohistochemical and in-vitro evaluation study. *Mr Zeger Rijs, Leiden University Medical Center, Leiden, Netherlands*

- 13.48 231 Development of a Targeted Dual-Modality Radioimmunoconjugate for Image Guided Sarcoma Surgery. *Dr Corey Chan, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom*
- 13.54 122 Feasibility of novel in-situ local tumor ablation and recycling machine using radiofrequency dielectric heating. *Dr Min Wook Joo, Department of Orthopaedic Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic*
- 14.00 Questions

#### MISCELLANEOUS PAPERS

- 14.10 53 Clinical and functional results following partial or total claviclectomy without reconstruction for malignant clavicular tumours. *Dr Maria Anna Smolle, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria*
- 14.16 243 Natural History, Risk Factors and Surgical Outcomes of Coxa Vara Deformity in Fibrous Dysplasia/McCune-Albright Syndrome. *Ms Maartje Meier, Leiden University Medical Center, Leiden, Netherlands*
- 14.22 285 Bioactive ceramics in the treatment of benign bone tumours and tumour-like lesions. *Prof Oleg Vyrva, Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine*
- 14.28 286 Aneurysmal bone cysts: a UK-wide tumour centre experience. *Mr Luckshman Bavan, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom*
- 14.34 Questions
- 14.44 61 The oncology orthopedist Role – where do we fit? *Dr Ana Cecilia Belzarena, Miami Cancer Institute, Miami, USA*
- 14.50 62 Freezing in Florida – Are we ready for diversity? *Dr Ana Cecilia Belzarena, Miami Cancer Institute, Miami, USA*
- 14.56 273 Long term follow up in a High-Grade Sarcoma of the arm encasing the Radial Nerve treated by ISP technique. *Dr Sreeraj Rajan, Aster MIMS, Calicut, India*
- 15.02 274 Low-grade Myofibroblastic Sarcoma of femur: A case report. *Dr Sreeraj Rajan, Aster MIMS, Calicut, India*
- 15.08 90 Isolated limb perfusion and tumour endoprosthesis: a perfect combination for bone-associated sarcomas, or have we gone completely bonkers? *Dr Lars Erik Podleska, Department of Orthopaedic Oncology and Sarcoma Surgery, Essen University Hospital, Essen, Germany*
- 15.14 Questions
- 15.24 **Close of Session**

#### 15.30 REFRESHMENTS